Bifogade filer
Bulletin from the Extraordinary General Meeting in LIDDS AB (publ) on the 9 January 2023
Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
The Extraordinary General Meeting in LIDDS AB (publ) (“LIDDS” or the “Company”) was held on 9 January 2023 and in particular the following decisions were resolved.
Approval of the resolution by the Board of Directors to issue new shares with preferential rights for the shareholders
The Extraordinary General Meeting resolved to approve the Board of Directors’ resolution of 16 December 2022, to increase the Company’s share capital by a maximum amount of SEK 1,841,208.92 through the issue of a maximum number of 34,739,791 shares.
The shareholders of the Company shall have preferential rights to subscribe for the new shares in relation the number of shares previously held, whereby one existing share entitles to subscribe for one new share. The record date for determining which shareholders shall be entitled to subscribe for new shares on a preferential basis shall be 18 January 2023. The subscription price is SEK 1.40 per share which in the case of full subscription provides issuing proceeds of up to approximately 48.6 MSEK.
Subscription for new shares based on subscription rights shall be made through payment in cash during the period from 23 January 2023 until and including 6 February 2023. Subscription without subscription rights shall be made through notice on special application form during the period from 23 January 2023 until and including 6 February 2023.
Authorisation for the Board of Directors to resolve on a new issue of shares in case of oversubscription (over-allotment option)
The Extraordinary General Meeting resolved to authorise the Board of Directors to, on one occasion, not later than 28 February 2023, decide on a new issue of shares in the event of oversubscription in the rights issue. The Company's share capital can be increased by a maximum of SEK 567,857.105 through a new issue of not more than 10,714,285 shares. The new shares shall be subscribed for with deviation from the shareholders' preferential rights. The purpose of the authorisation and the reason for the deviation from the shareholders' preferential rights is the possibility of bringing additional capital to the Company (so-called over-allotment option).
Authorisation for the Board of Directors to resolve on a new issue of shares for compensation to guarantors
The Extraordinary General Meeting resolved to authorise the Board of Directors to, on one occasion, no later than 28 February 2023, resolve on a new issue of shares to guarantors in the rights issue. The Company's share capital shall be increased by a maximum of SEK 189,891.421 through a new issue of a not more than 3,582,857 shares at a subscription price of SEK 1.40 per share. The new shares shall be subscribed for with deviation from the shareholders' preferential rights. The purpose of the authorisation and the reason for the deviation from the shareholders' preferential rights is to pay compensation to such guarantors in the rights issue who have chosen to receive the guarantee compensation in the form of newly issued shares.
Notice and complete proposals are available on the company's website: https://liddspharma.com/en/corporate-governance/